Page 10 - Sun Pharma

Sun Pharma gains 5% as Sebi finds no merit in allegation of fraud

HDFC Securities has 'buy' rating on Sun Pharma with a 12-month target price of Rs 545 as the brokerage expects a recovery in the profitability (24 per cent margin) by FY21E.

Sebi inquiry clears Sun Pharma, finds no merit in allegations of fraud

The investigation team is of the view that the matter does not require further probe, said sources. The team sent its report to the Sebi committee for vetting

Sun Pharmaceutical's US specialty ramp-up still slow, say experts

Sun's focus on specialty comes at a time when its US revenues are under pressure owing to competitive intensity

Sun Pharma announces tie-up for China foray; to develop 8 generic products

The total addressable market size for all these eight products is about $1 billion (according to recent IQVIA data) in mainland China

Sun Pharma signs global licensing pact with CSIR-IICT for patents

The pact is for patents related to certain compounds with potential therapeutic activity across multiple indications

Nifty Pharma index hits 5-year low; Glenmark at 7-year low post Q1 results

Glenmark Pharmaceuticals plunged 9 per cent, while Dr Reddy's slipped 8 per cent in intra-day trade

Global business growth, lower costs a booster dose for Sun Pharma

Company focusing on specialty portfolio to drive US growth

Sun Pharma Q1 net rises 31% to Rs 1,387 crore on lower R&D expenses

India's largest drugmaker has raised focus on specialty and limited competition products in the wake of pricing pressure in the US

Sun Pharma net profit up 31% at Rs 1,387 cr in June quarter of FY20

The company had posted a profit of Rs 1,057.29 crore for the corresponding period of the previous fiscal, Sun Pharma said in a filing to BSE

Nilesh Gupta to Dilip Shanghvi, most pharma CEOs took a pay cut in FY19

The CEOs' salaries also have taken a brunt. A quick analysis shows that Shanghvi took a whopping 99 per cent pay cut

Sun Pharma shuts two clinical units in Vadodara for cost efficiency

Drug major Sun Pharma on Saturday said it is discontinuing operations at two clinical pharmacology units in Vadodara (Gujarat) to bring in efficiencies in cost and processes. "While we continue to make investments in our R&D operations, we also constantly evaluate our resources and future capacity requirements to bring in efficiencies in cost and processes," a Sun Pharmaceutical Industries spokesperson said in a statement. To ensure optimal utilisation of clinical pharmacology units (CPUs) that conduct bio-equivalence studies, the company is discontinuing operations at two centers at Tandalja and Akota in Vadodara, the spokesperson added. "The bio-equivalence studies from these centers will be transferred to our other facilities. We are offering full support to the affected employees and helping them with out placement services," the spokesperson said. As per industry sources, the move would impact around 80 staffers at the two locations. Sun Pharma has six major R&D centers ..

Sun Pharma shuts down two R&D units in Vadodara; lays off some employees

Market sources peg the number at 85 personnel who have been terminated and given three months salary in advance

Dilip Shanghvi takes 99% pay cut despite Sun Pharma's 27% earnings growth

Shanghvi, one of the lowest-paid CEOs in India's pharmaceutical sector, drew a salary of Rs 1 during 2018-19

Sun Pharma aims to clock 'low-to-mid teens' growth in revenues in FY20

Drug major Sun Pharmaceutical Industries is gradually ramping up its speciality business across global markets as it aims to clock "low-to-mid teens" growth in consolidated revenues in the current fiscal. Addressing shareholders in the company's annual report for 2018-19, Sun Pharma Managing Director Dilip Shanghvi said the company is focused at growing each of its business verticals faster than the market in which it operates. "Our consistent focus is on growing each of our businesses faster than the market in which they operate. Our global specialty initiatives will supplement this objective as an additional growth engine," Shanghvi said. The company is targeting key ailments like psoriasis to gradually ramp up its global specialty business, he said adding that Sun Pharma would continue to invest in branding and promotion of its various specialty products. Besides, R&D investments for funding clinical trials of some of the specialty products are also likely to continue in ...

Sun Pharma bets on nurturing specialty portfolio outlook; stock rises 3.6%

Street is bullish on stabilising US generics sales, upsides from niche portfolio, and inexpensive valuations

Sun Pharma gains for fifth straight day on Morgan Stanley's upgrade

In the past one week, Sun Pharma has outperformed the market by surging 16 per cent, as compared to 0.20 per cent decline in the S&P BSE Sensex

Sun Pharma launches drug in US to treat lipid-linked swallowing problems

Ezallor Sprinkle (rosuvastatin) capsules is indicated for three types of lipid disorders in conjunction with diet in adults

Five reasons why Morgan Stanley has turned bullish on Sun Pharma

The global brokerage firm said Sun Pharma was its top pick in its Indian healthcare coverage and sees 27 per cent upside potential in the stock

Sun Pharmaceutical gets four observations for Halol facility in Gujarat

The regulator has also observed that lab control mechanisms were not documented

Sun Pharma Q4 profit halves to Rs 636 cr on distribution strategy change

Sales in the US were $443 million for the quarter, a 20 per cent increase over the same period last year, and accounted for 44 per cent of total sales